NASHVILLE, Tenn., Aug. 30 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of new data supporting the safety and efficacy of Caldolor® (ibuprofen) Injection in pre and post-operative orthopedic surgery patients.
Caldolor® (Ibuprofen) Injection Shown to Significantly Reduce Fever in Malaria Patients in Newly Published Clinical Trial
NASHVILLE, Tenn., July 12 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene.
Horizon Pharma Announces LODOTRA(R) and DUEXA(R) Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress
NORTHBROOK, Ill., June 9 /PRNewswire/ -- Horizon Pharma, Inc., today announced that data on its two lead product candidates, LODOTRA®, a circadian cytokine modulator and novel modified release, low-dose prednisone tablet, and DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, will be presented during the European League Against Rheumatism (EULAR) Annual Congress taking place in Rome, Italy, June 16-19.